Exelixis, Inc. (EXEL) is a leading biopharmaceutical company that is ideally positioned to focus on the discovery, development, and commercialization of new and innovative medicines that can drastically enhance the lives of patients battling cancer. The company is headquartered in Alameda, California, and has been in operation since 1994.
Exelixis is best known for its targeted therapy drug, Cabometyx (cabozantinib), which is approved for the treatment of several types of cancers, including advanced renal cell carcinoma (RCC, a type of kidney cancer) and hepatocellular carcinoma (HCC, a type of liver cancer). The drug works by blocking the growth of new blood vessels that feed a tumor. Apart from Cabometyx, Exelixis has also developed other drugs such as Cometriq and Cotellic, and is continuously working on new drug candidates to further expand its product portfolio.
The company operates on a business model that combines internal product development with strategic corporate alliances and business development activities. This strategy has allowed Exelixis to access resources, share risk and attract significant capital over the course of its existence, thereby building a robust product pipeline and achieving financial stability.
Exelixis, Inc. is deeply committed to the principle of doing "good science that matters." The company employs a team of skilled, passionate professionals who are relentless in their pursuit of new scientific understandings and clinical breakthroughs. Exelixis highly values collaboration, teamwork, and integrity, ensuring a conducive working environment for innovation to flourish.
Corporate social responsibility is also a key component of Exelixis' mission. The company is committed to improving access to its therapies, supporting patient groups and contributing to the broader community. It is also focused on reducing its environmental impact and promoting sustainable practices.
On the financial front, Exelixis continues to deliver strong performance with a steady stream of revenue from its approved products and clinical developments. It has a solid balance sheet with sufficient liquidity to meet its expansion requirements and uphold research and development activities.
In the ever-evolving biopharmaceutical industry, Exelixis offers a compelling mix of current successful cancer treatments and promising pipeline products, a sound business strategy, robust financial health and a strong commitment to patients. This positions them firmly for continued growth and further achievements in their mission to help cancer patients recover stronger and live longer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Exelixis (EXEL) saw its stock return 76.0% between October 2025 and October 2026, significantly outperforming the S&P 500. This surge followed the FDA's acceptance of its experimental cancer drug, zanzalintinib, which the company had been highlighting to investors since February 2025. Despite public trial results showing positive outcomes, the stock's major run-up occurred later when the regulatory process advanced.
Exelixis, Inc. published its slide deck in conjunction with its Q3 2026 earnings call. This presentation provides details on the company's financial results for the third quarter. The article was written by the Seeking Alpha transcripts team.
Exelixis Inc. (EXEL) reported a strong third quarter, with profits reaching $218.1 million or 85 cents per share. Adjusted earnings of 94 cents per share surpassed analyst expectations of 89 cents. The drug developer also exceeded revenue forecasts, posting $658.7 million against an expected $653.1 million, and provided a full-year revenue outlook between $2.5 billion and $2.55 billion.
Exelixis is approaching its third-quarter earnings report with a discrepancy between its lowered 2026 revenue guidance and the Street's higher consensus estimates, prompting a critical evaluation of its outlook. The company had previously cut its full-year forecast due to a slower ramp-up for cabozantinib in neuroendocrine tumors, yet its stock has rallied since. The upcoming report will determine if the guidance cut was conservative or indicative of a softer growth period, with analysts expecting non-GAAP earnings of $0.89 a share on revenue of $653.1 million.
Citizens has maintained a 'Market Outperform' rating for Exelixis (EXEL), increasing its price target to $65.00, suggesting confidence in the company's growth potential. Despite this positive outlook, GuruFocus indicates EXEL is 32.3% overvalued at its current price of $62.23, and insider selling has been observed. Investors are advised to consider the strong GF Score against the overvaluation and insider activity.
Exelixis, Inc. (Nasdaq: EXEL) announced that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after market close. Following the release, Exelixis management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Details for accessing the conference call and webcast replay are available on the company's website.